{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:43:29Z","timestamp":1791431009749,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7224324"],"award-info":[{"award-number":["7224324"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jiph.2023.11.018","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:07:45Z","timestamp":1700514465000},"page":"137-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data"],"prefix":"10.1016","volume":"17","author":[{"given":"Shanshan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoju","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-9807","authenticated-orcid":false,"given":"Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2023.11.018_bib1","unstructured":"World Health Organization; 2022. Global tuberculosis report 2022. Geneva: Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.jiph.2023.11.018_bib2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/resp.13304","article-title":"Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment","volume":"23","author":"Lange","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.jiph.2023.11.018_bib3","first-page":"1314","article-title":"Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia","volume":"11","author":"Shin","year":"2007","journal-title":"Int J Tube Lung Dis"},{"key":"10.1016\/j.jiph.2023.11.018_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jinf.2017.12.017","article-title":"Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China","volume":"76","author":"Xu","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.jiph.2023.11.018_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijid.2018.03.002","article-title":"Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - \"Wanted: Leaders for a TB-Free World. You can make history. End TB","volume":"68","author":"Tiberi","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2023.11.018_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032976","article-title":"Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China","volume":"7","author":"Pang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jiph.2023.11.018_bib7","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(13)62639-2","article-title":"Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data","volume":"383","author":"Wang","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2023.11.018_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(16)30418-2","article-title":"Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation","volume":"17","author":"Yang","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2023.11.018_bib9","doi-asserted-by":"crossref","first-page":"g1083","DOI":"10.1136\/bmj.g1083","article-title":"China's misuse of antibiotics should be curbed","volume":"348","author":"Li","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2023.11.018_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.149205","article-title":"A systematic review on antibiotics misuse in livestock and aquaculture and regulation implications in China","volume":"798","author":"Shao","year":"2021","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.jiph.2023.11.018_bib11","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2023.11.018_bib12","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.jiph.2023.11.018_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline drug resistance emergence assessment in multidrug-resistant tuberculosis (MDR-TB): a 5-year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates","volume":"60","author":"Kaniga","year":"2022","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jiph.2023.11.018_bib14","doi-asserted-by":"crossref","first-page":"e3391","DOI":"10.1093\/cid\/ciaa1002","article-title":"Reduced susceptibility of mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China","volume":"73","author":"Liu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2023.11.018_bib15","unstructured":"World Health Organization; 2018. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.jiph.2023.11.018_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2016.111","article-title":"Risk factors for pulmonary cavitation in tuberculosis patients from China","volume":"5","author":"Zhang","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jiph.2023.11.018_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/AAC.01611-09","article-title":"Rates and mechanisms of resistance development in mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor","volume":"54","author":"Huitric","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2023.11.018_bib18","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-Resistance between clofazimine and bedaquiline through upregulation of mmpl5 in mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2023.11.018_bib19","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1128\/AAC.00753-16","article-title":"Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in mycobacterium tuberculosis","volume":"60","author":"Almeida","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2023.11.018_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","article-title":"Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2023.11.018_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jgar.2020.11.011","article-title":"Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavourable interim microbiological treatment outcome: an observational study","volume":"24","author":"Singh","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jiph.2023.11.018_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijid.2014.03.1388","article-title":"Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates","volume":"26","author":"Ho","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2023.11.018_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijid.2020.01.021","article-title":"Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene","volume":"92","author":"Huo","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2023.11.018_bib24","unstructured":"Yiruhan, Wang Qj. Fau- Mo.C.-H., Mo Ch Fau - Li.Y.-W., Li Yw Fau - Gao P., Gao P.Fau- Tai Y.-P., Tai Yp. Fau- Zhang Y., Zhang Y Fau - Ruan Z.-L., Ruan Zl Fau - Xu.J.-W., Xu J.W. Determination of four fluoroquinolone antibiotics in tap water in Guangzhou and Macao."},{"key":"10.1016\/j.jiph.2023.11.018_bib25","unstructured":"Qiao M., Ying G.G., Singer A.C., Zhu Y.G. Review of antibiotic resistance in China and its environment."},{"key":"10.1016\/j.jiph.2023.11.018_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ebiom.2018.01.005","article-title":"Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study","volume":"28","author":"Ismail","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jiph.2023.11.018_bib27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jinf.2020.01.007","article-title":"Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates","volume":"80","author":"Peretokina","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jiph.2023.11.018_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cmi.2020.06.004","article-title":"Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study","volume":"27","author":"Gao","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2023.11.018_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01677-19","article-title":"Validation of bedaquiline phenotypic drug susceptibility testing methods and breakpoints: a multilaboratory, multicountry study","volume":"58","author":"Kaniga","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jiph.2023.11.018_bib30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/AAC.01228-13","article-title":"Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2023.11.018_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1056\/NEJMc2103049","article-title":"Bedaquiline-resistant tuberculosis associated with Rv0687 mutations","volume":"386","author":"Omar","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2023.11.018_bib32","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1128\/AAC.02941-15","article-title":"Mutations associated with reduced susceptibility to linezolid","volume":"60","author":"Zhang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2023.11.018_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s13756-021-00995-8","article-title":"Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition","volume":"10","author":"Yao","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jiph.2023.11.018_bib34","doi-asserted-by":"crossref","unstructured":"Mirzayev F., Viney K., Linh N.N., Gonzalez-Angulo L., Gegia M., Jaramillo E., Zignol M., Kasaeva T. 2021. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J 57.","DOI":"10.1183\/13993003.03300-2020"},{"key":"10.1016\/j.jiph.2023.11.018_bib35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123004057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123004057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:23:45Z","timestamp":1761751425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034123004057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1876034123004057"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2023.11.018","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2023.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}